Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 9 | 9 |
| 2001 | 1 | 11 | 12 |
| 2002 | 0 | 22 | 22 |
| 2003 | 0 | 13 | 13 |
| 2004 | 0 | 17 | 17 |
| 2005 | 4 | 16 | 20 |
| 2006 | 2 | 35 | 37 |
| 2007 | 1 | 40 | 41 |
| 2008 | 2 | 46 | 48 |
| 2009 | 5 | 40 | 45 |
| 2010 | 12 | 74 | 86 |
| 2011 | 5 | 87 | 92 |
| 2012 | 5 | 85 | 90 |
| 2013 | 3 | 87 | 90 |
| 2014 | 4 | 113 | 117 |
| 2015 | 5 | 108 | 113 |
| 2016 | 5 | 131 | 136 |
| 2017 | 9 | 121 | 130 |
| 2018 | 8 | 106 | 114 |
| 2019 | 6 | 112 | 118 |
| 2020 | 2 | 105 | 107 |
| 2021 | 6 | 88 | 94 |
| 2022 | 0 | 18 | 18 |
| 2023 | 0 | 8 | 8 |
| 2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Peritoneal Microenvironment Promotes Appendiceal Adenocarcinoma Growth: A Multi-omics Approach Using Patient-Derived Xenografts. Mol Cancer Res. 2024 Apr 02; 22(4):329-336.
-
The Power and Promise of Patient-Derived Xenografts of Human Breast Cancer. Cold Spring Harb Perspect Med. 2024 Apr 01; 14(4).
-
Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo. Acta Biomater. 2024 Apr 01; 178:83-92.
-
Histopathologic and immunophenotypic characterization of patient-derived pediatric malignant hepatocellular tumor xenografts (PDXs). Pathol Res Pract. 2024 Mar; 255:155163.
-
Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases. J Clin Invest. 2023 Dec 15; 133(24).
-
Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer. Nat Commun. 2023 Nov 22; 14(1):7600.
-
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer. Clin Cancer Res. 2023 08 15; 29(16):3237-3249.
-
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. Neuro Oncol. 2023 07 06; 25(7):1249-1261.
-
Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models. J Transl Med. 2023 07 06; 21(1):444.
-
An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma. J Neurooncol. 2023 Jul; 163(3):635-645.